AstraZeneca to strengthen therapy area franchise through acquisition of Takeda’s respiratory business
Acquisition to include non-US rights to roflumilast and will beaccretive to 2016 earnings, contributing to AstraZeneca’s return to growth strategy
-
-
Discussions with Acerta Pharma BV
Further to recent speculation, AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction.
The Company will make a further announcement if and when appropriate.
– ENDS –
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a global, -
AstraZeneca i samarbete med nytt svenskt center för proteinforskning för utveckling av nästa generations läkemedel genom sekretomforskning
AstraZeneca och koncernens globala forsknings- och utvecklingsbolag för biologiska läkemedel, Medimmune, meddelar idag ett treårigt samarbete med det nybildade forskningscentret Wallenberg Centre for Protein Research (WCPR).
-
AstraZeneca enters into agreement with Perrigo for rights to Entocort® in the US
Divestmentfurther sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015
-
AstraZeneca and Sanofi exchange over 200,000 chemical compounds
AstraZeneca and Sanofi today announced a direct exchange of 210,000 compounds from their respective proprietary compound libraries. The swap represents a novel open innovation model between pharmaceutical companies.
-
AstraZeneca expands technological investment in new Cambridge lead discovery centre
AstraZeneca today announced three new partnerships that will deliver industry-leading technologies to drive the AstraZeneca MRC UK Centre for Lead Discovery in the search for novel small molecule medicines. The partnerships will ensure state-of-the-art screening and compound management at the facility, which will be located within the company’s new global R&D centre at the Cambridge Biomedical
-
Tagrisso™ (AZD9291) approved by the US FDA for patients with EGFR t790m mutation-positive metastatic non-small cell lung cancer
One of fastest development programmes – from start of clinical trials to approval in just over two and a half years to meet unmet patient need With objective response rate of 59% and duration of response of 12.4 months, TAGRISSO provides important new option for patients
-
Outtröttlig bröstcancerkämpe får prestigetyngd utmärkelse
BRO:s Utmärkelse 2015 tilldelas Helena Janlöv-Remnerud, sjuksköterska och medicinsk lymfterapeut, hemmahörande i Edsbro i Uppland.
-
PEGASUS-TIMI 54 SUB-ANALYSIS OUTLINES LONG-TERM TOLERABILITY DATA FOR BRILIQUE
Data presented at AHA suggests benefit in patients who stayed on Brilique (ticagrelor) treatment.
-
AstraZeneca presents positive new data on anifrolumab in lupus at American College of Rheumatology Annual Scientific Meeting
Anifrolumab met primary and secondary endpoints in Phase II, significantly reducing lupus disease activity compared with placebo across multiple endpoints
-
AstraZeneca strengthens cardiovascular and metabolic disease portfolio with acquisition of ZS Pharma
AstraZeneca to acquire ZS Pharma for $90 per share Acquisition includes potential best-in-class hyperkalaemia treatment currently under US FDA regulatory review
-
Delårsrapport AstraZeneca PLC för de första nio månaderna och tredje kvartalet 2015
Pascal Soriot, koncernchef, kommenterar resultatet: "Jag är nöjd med framstegen vi gör. Vi fortsätter att fokusera på genomförandet av våra planer för tillväxtplattformarna och forskningsportföljen.
Visa mer
Loading...